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PREVALENCIA, MANIFESTACIONES CLÍNICAS Y FACTORES ASOCIADOS AL
COVID-19 DE LARGA DURACIÓN
Daniel Rojas-Bolivar 1,a, Fabiola Huaroto-Ramírez 1,b, Maricela Curisinche-Rojas 1,c
Diana Gonzales Zurita1,a, Ericson Gutiérrez1,2,d

ABSTRACT
Objective: The objective was to describe the prevalence, clinical manifestations, and associated factors of long
the COVID-19. Methods: A bibliographic search of systematic reviews and meta-analyses on long COVID-19
was carried out in MEDLINE (via PubMed) up to April seven th, 2022. 37 articles were found and three were
included. Results: The quality of the evidence was evaluated through AMSTAR 2 criteria. The reported
prevalence of long COVID-19 was 43% (95% CI: 39% – 46%). The main clinical manifestations were weakness
(41% [95% CI: 25% - 59%]), malaise (33% [95% CI: 15% - 57%]), fatigue (31% [95% CI: 24% - 39% %]), changes in
concentration (26% [95% CI: 21% – 32%]) and shortness of breath (25% [95% CI: 18% – 34%]). Conclusion:
Factors associated with long COVID-19 include female gender, the severity of initial symptoms, age, and the
presence of comorbidities.

RESUMEN
Objetivo: El objetivo fue describir la prevalencia, las manifestaciones clínicas y los factores asociados de COVID19 de larga duración. Métodos: Se realizó una búsqueda bibliográ ca de revisiones sistemáticas y metaanálisis
sobre COVID-19 de larga duración en MEDLINE (vía PubMed) hasta el siete de abril de 2022. Se encontraron 37
artículos y se incluyeron tres. La calidad de la evidencia fue evaluada a través de los criterios de AMSTAR 2.
Resultados: La prevalencia reportada de COVID-19 de larga duración fue 43% (IC95%: 39% – 46%). Las
principales manifestaciones clínicas fueron debilidad (41% [IC95%: 25% – 59%]), malestar general (33% [IC95%:
15% – 57%]), fatiga (31% [IC95%: 24% – 39%]), alteración en la concentración (26% [IC95%: 21% – 32%]) y
sensación de falta de aire (25% [IC95%: 18% – 34%]). Conclusión: Los factores asociados a COVID de larga
duración incluyeron sexo femenino, severidad de cuadro inicial, edad y presencia de comorbilidades.
Palabras clave: COVID-19, síndrome de COVID-19 post-agudo, COVID-19 de larga duración. (Fuente: DeCS
BIREME)
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INTRODUCTION

history of SARS-CoV-2 infection, what is the prevalence

COVID-19 has been characterized by its acute clinical

of long COVID-19 and the frequency of long COVID-19

manifestations, including fever, cough, dyspnea, and

symptoms? And, in adults with a history of SARS-CoV-2

fatigue

infection, what are the factors associated with the

(1,2)

; As the disease progresses, approximately

10% of patients require intensive care (3). Although it is

presentation of long COVID-19?

true that most people who contract COVID-19 fully
recover, there is a proportion that reported persistence
of symptoms in the medium and long term (4-6) , this
picture is called by some researchers COVID-19 of long
duration (long COVID) (4,7,8).
Despite the existence of cases of people with persistent

Search and selection of evidence
The bibliographic search was carried out in MEDLINE
(via PubMed), through a search strategy that included
free terms and controlled language descriptors for long
COVID-19 (Supplementary material one: search
strategy), the search was carried out until April seven th,
2022.

symptoms after SARS-CoV-2 infection, there is still no
clear consensus on the de nition of long the COVID-19.

The selection of the articles was carried out individually

On the one hand, there is research evaluating the

by the authors, considering an initial phase of reading

sequelae of the COVID-19(1,9) , on the other hand, others

the titles and abstracts through the Rayyan platform

de ne it as post-acute COVID-19 syndrome or PACS(10,11) ,

(www.rayyan.ai) and a phase of reading the full text of

as well as there is also a de nition of the post-COVID

the potentially relevant publications to determine their

syndrome

eligibility. The inclusion criteria were:

. Such diﬀerences result in diﬀerent

(12,13)

estimates of prevalence, as well as diﬀerent clinical
implications. In this sense, the WHO de ned long

1) systematic reviews and meta-analyses of cohort,

COVID-19 as “the disease contracted by people with a

case-control, or cross-sectional studies that report

history of probable or con rmed SARS-CoV-2 infection;
usually within three months of the onset of COVID-19
and with symptoms or eﬀects lasting at least two
months” (14).

results for outcomes of interest, evaluated at least three
months from the onset of COVID-19 in adults; 2) reviews
published in English and Spanish. If more than one
systematic review was identi ed, the one with the best
methodological quality was chosen. The following were
excluded: 1) systematic reviews that had not assessed

Research has considered diﬀerent de nitions,

the risk of bias or the methodologic quality of the

outcomes, and follow-up times, so the state of

included studies; 2) systematic reviews focused on

knowledge about long COVID-19 is still insuﬃcient. Our

determining the prevalence of symptoms of a single

objective was to synthesize the available scienti c

organ or system and 3) letters to the editor, narrative

information from systematic reviews regarding the

reviews, preclinical studies (studies in vitro or animal

prevalence, clinical manifestations, and associated

models), and opinion articles.

factors of long COVID-19. The information presented
was part of the evidence synthesis report prepared by
the National Health Institute at the request of the
Peruvian Ministry of Health(15).

METHODOLOGY
Question formulation
Two clinical questions were formulated: in adults with a
Pág. 573
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Data extraction
The data was extracted in a standardized form that
included the following information: author, year of
publication, number of studies included in the review,
number of participants, design, place, population
characteristics, prevalence outcomes, associated
factors, and assessment tool. risk of bias assessment and
AMSTAR 2 score.
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Assessment of methodological quality and risk
of bias
(16)

After reading the titles and abstracts, 17 articles were
selected for full-text reading. Finally, after verifying

was used to assess the

eligibility criteria and applying the AMSTAR 2 criteria, 3

methodological quality of identi ed systematic

systematic reviews were selected for data synthesis

reviews. The evaluation was carried out by four authors

(Figure 1), one of them was peer-reviewed and

(FHR, DG, DR, MCR) in a paired and independent

published after the search, considering the information

manner and discrepancies were resolved by consensus.

provided by this latest version (9). Excluded articles and

The risk of bias in the included studies was considered

reasons for exclusion are described in Supplementary

from the reviews with the best AMSTAR 2 score.

Material.

RESULTS

2. The main characteristics of the selected systematic

37 articles were identi ed in the bibliographic search.

reviews are summarized in Table 1.

37 references identi ed via
MEDLINE (PubMed)
Total n = 37

Screened titles and abstracts
n = 37

Excluded titles and abstracts
n = 22

Eligibility

Eligible for screening
n = 37

Full texts evaluated for
eligibility
n = 17

Full texts excluded
n = 14

Included

Screening

Identi cation

The AMSTAR 2 tool

Included studies
n=3

Figure 1. PRISMA diagram for study selection.
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Table 1. Characteristics of the selected systematic reviews.

Characteristics of the studies
The study by Chen et al. was a systematic review and
(9)

meta-analysis that aimed to examine the prevalence of
post-acute sequelae of the COVID-19 around the world
. The databases consulted were PubMed, Embase, and

(9)

The search identi ed 5 125 studies, from which 40 were
included for qualitative synthesis, and 33 for metaanalysis (number of participants: 886 388). The selected
studies were of the prospective cohort type (n = 23),
retrospective cohort (n = 6), bidirectional cohort (n = 3),
and cross-sectional studies (n = 8).

iSearch for studies without peer review (preprints) of
medRxiv, bioRxiv, Social Science Research Network
(SSRN), and others (search performed on July 5, 2021,
with an extension to March 13 of 2022). Studies in
English that evaluated long the COVID-19, de ned as
conditions that persist for at least 28 days after
diagnosis or recovery from SARS-CoV-2 infection, were
selected. The outcomes evaluated were prevalence, risk
factors, duration, or associated symptoms.
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The risk of bias assessment was carried out using the
Joanna Briggs Institute tool for studies with prevalence
results, for which they added the total responses
classi ed as "Yes" concerning nine questions of the tool
(score from zero to nine) where Aspects such as the
representativeness of the population included
(sampling framework, sampling), the size of the sample,
the description of the population and the environment,
the methods to evaluate the study condition, the
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statistical analysis and the percentage of response of

out on diagnostic imaging (13 of 39; diagnostic

the participants . After updating the search to March

methods included tomography, ultrasound, and

13, 2022, an additional ten studies were included for

arti cial intelligence) and functional tests (ten of 39;

qualitative synthesis, of which eight were included in

methods included spirometry, diﬀusing capacity, lung

the meta-analysis. The selected studies were of the

volume, and exercise tests). The risk of bias was

(17)

prospective cohort type (n = 5), retrospective cohort (n

evaluated with the instrument developed by Hoy et al.

= 1), bidirectional cohort (n = 3), and cross-sectional

(18)

studies (n = 1).

, which is a validated tool for bias assessment in

prevalence studies. The studies had a low risk of bias
(4/39), moderate risk (23/39), and high risk (12/39). The

The total number of participants after the new

domains that presented more studies with a high risk of

systematic search was 1,680,003. The characteristics of

bias were: 1) representation of the national population

the participants were: non-hospitalized participants

(21 of 39 studies), 2) true sampling frame or close

(4,165 of 5 studies), hospitalized participants (67,161 of

representation of the target population (24 of 39) and 3)

22 studies), and any the COVID-19 positive patient,
regardless of their hospitalization status (1,608,677 of

random selection used for sample selection (32 of 39
studies).

23 studies). According to the risk of bias assessment
with the Joanna Briggs Institute tool, the most frequent
methodological limitations were: sampling was not
adequate (16 of 50 studies), a valid method was not
used to identify the study condition (15 of 50 studies),
the sampling frame was not appropriate to address the
target population (seven of 50 studies) and the data
analysis was not performed with suﬃcient coverage of
the identi ed sample (seven of 50 studies).
The study by Michelen et al. (8) aimed to synthesize the
evidence on the characteristics of long-lasting COVID19 (8). The study design was of the living systematic
review type. The authors performed the systematic
search in the MEDLINE, CINAHL, Global Health (Ovid),

The study by Maglietta et al. (12) aimed to identify, in
patients who had been hospitalized for the COVID-19,
which factors were already present or emerging during
hospitalization, It was associated with a higher risk of
presenting new or persistent symptoms (12). The study
design was a systematic review and a bibliographic
search was carried out in two databases (MEDLINE and
Web of Science) until September 20, 2021, including
observational studies in English, with 12 weeks or more
of prospective follow-up. Odds ratios were estimated
for each assessed factor using unadjusted data. They
also performed a random eﬀects meta-analysis, using
the Paule and Mandel method for estimating variance
between studies (19,20). The con dence intervals for the
global eﬀect of the factors of interest were adjusted by

WHO Global Research on the COVID-19, LitCOVID, and

applying the Hartung-Knapp-Sidik-Jonkman (HKSJ)

Google Scholar databases (search period from January

approach, which takes into account the uncertainty in

one, 2002, to March 17, 2021). The outcomes evaluated

the variance of the estimates (21).

were the prevalence of signs and symptoms and
associated factors. A total of 39 studies were selected

Risk of bias assessment was performed using the QUIPS

(cohort studies: 32; cross-sectional studies: six; case-

tool (22). This review provides evidence based on 20

control studies: one).

observational studies and association measures for the
factors of gender and severity of the initial condition

The total number of participants was 10 951 (48%

concerning outcomes such as any symptoms,

women) from 12 countries. The main nding was the

respiratory symptoms, mental health symptoms, and

estimation of the prevalence of symptoms of long

fatigue. Most studies (11 of 20) were rated as high risk of

COVID, in addition, a qualitative synthesis was carried

bias in at least one domain of the QUIPS tool and
Pág.576
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included: loss of participants to follow up (ten studies),
the study sample was not representative of the
population of interest (four studies), limitations in
statistical analysis and reporting of results (three
studies), and potential confounders not adequately
addressed (one study). The remaining studies (nine of
20) were at moderate risk of bias.

group it was 0.34 (95% CI: 0.25 - 0.36), and in the mixed
group between hospitalized and non-hospitalized was
0.33 (95% CI: 0.29 – 0.37).
According to the follow-up time, the prevalence of PACS
after 90 days was 0.32 (95% CI: 0.14 – 0.57), while the
prevalence after 120 days was 0.49 (95% CI: 0.40 – 0.59).

Prevalence of long-term clinical manifestations
of COVID-19

Prevalence of Long COVID-19
According to Chen et al. (9) , the overall prevalence of
post-acute COVID-19 syndrome was 0.43 (95% CI: 0.39 –
0.46) (I2 = 100%; p < 0.001). The authors strati ed the
analysis according to sex, region, hospitalization, and
follow-up time. According to sex, the prevalence of
PACS in men was 0.37 (95% CI: 0.24 – 0.51) and in
women, 0.49 (95% CI: 0.35 – 0.63); while, by region, the
highest prevalence was found in Asia (0.51 [95% CI: 0.37
– 0.65]), followed by Europe (0.44 [95% CI: 0.32 – 0.56])
and the United States (0.31 [95% CI: 0.21 – 0.43]);
According to the history of hospitalization, the
prevalence in hospitalized the COVID-19 patients was
0.54 (95% CI: 0.44 - 0.63), in the non-hospitalized

According to Chen et al. (9) , the most frequent clinical
manifestations of PACS were: fatigue (prevalence: 0.23
[95% CI: 0.17 – 0.30]), memory problems (0.14 [95% CI:
0.10 – 0.19]), dyspnea (0.13 [95% CI: 0.11 – 0.15]),
insomnia (0.11 [95% CI: 0.05 – 0.23]), and joint pain (0.10
[95% CI: 0.04 – 0.22]).
On the other hand, according to Michelen et al. (8) , the
most frequent clinical manifestations were weakness
(prevalence: 41% [95% CI: 25.43 - 59.01]), malaise (33%
[95% CI: 14.91 - 57.36]), fatigue (31% [95% CI: 23.91 –
39.03]), altered concentration (26% [95% CI: 20.96 –
31.73]), and shortness of breath (25% [95% CI: 17.86 –
33.97]). The list of signs and symptoms is described in
Table 2.

Table 2. Prevalence of signs and symptoms of long COVID-19, according to the meta-analysis
by Michelen (2021)
Number of
studies

Proportion (95 % CI)

Heterogeneity
I2 (%)

Neurological and neuromuscular
Headache

11

4.88 (2.30 – 10.06)

94.88

Tremor

3

3.53 (0.30 – 30.63)

89.14

Seizures

1

1.33 (0.49 – 2.87)

NA

Bradykinesia

1

5.19 (2.11 – 10.39)

NA

Dissymmetry

1

1.48 (0.18 – 5.25)

NA

Muscular atrophy

1

6.67 (3.09 – 12.28)

NA

Altered muscle tone

1

4.44 (1.65 – 9.42)

NA

Altered gait or posture

3

4.20 (2.02 – 8.53)

0

Taste disturbance

17

13.52 (8.96 – 19.89)

96.75

Alteration of smell

19

15.17 (10.75 – 20.97)

96.2

Hearing disturbance

1

1.11 (0.36 – 2.57)

NA

Vision disturbance

2

4.78 (3.32 – 6.83)

26.01
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Nº estudios

Proporción (IC95%)

Heterogeneidad
I2 (%)

Dysarthria/speech diﬃculty

1

2.22 (0.46 – 6.36)

NA

Sensation of decreased sensitivity

2

10.90 (6.71 – 17.22)

71.76

Paresthesia

2

9.12 (2.21 – 30.87)

93.07

Trigeminal neuralgia

1

3.28 (0.90 – 8.18)

NA

Impaired re exes

1

22.96 (16.17 – 30.98)

NA

Others

1

14.81 (9.29 – 21.95)

NA

Anxiety

7

18.73 (8.89 – 35.35)

97.2

Depression

6

8.06 (4.14 – 15.10)

97.45

Sleep disturbance

9

18.15 (9.61 – 31.63)

93.87

Post-traumatic stress disorder

6

9.14 (3.66 – 21.04)

96.44

Dysphoria

3

1.79 (0.00 – 98.74)

97.83

Reduced quality of life

3

36.76 (18.43 – 59.83)

91.07

Care dependency

3

5.89 (0.46 – 45.96)

98.37

Memory disturbance

5

17.94 (5.26 – 46.25)

95.08

Altered concentration

2

25.98 (20.96 – 31.73)

0

Confusion

2

2.71 (1.93 – 3.79)

0

Frontal Release Signs

1

14.81 (9.29 – 21.95)

NA

Others

3

17.77 (0.08 – 98.23)

98.68

Skin rash

4

2.83 (0.95 – 8.16)

80.76

Hair loss

5

14.34 (5.33 – 33.23)

94.64

Conjunctivitis

1

1.77 (0.77 – 3.47)

NA

Psychological and social

Neurocognitive

Others

A strati cation was per for med according to
hospitalization status for the COVID-19 and it was found
that the prevalence of clinical manifestations was
signi cantly higher in hospitalized patients, compared
to non-hospitalized patients with fatigue (hospitalized:
37.10% [95% CI: 26.54 – 49.06]; not hospitalized: 24.6%
[95% CI: 20.11 – 29.72]; p = 0.012), shortness of breath
(hospitalized: 28.7% [95% CI: 18.48 – 41.64]; no
hospitalized: 13.7% [95% CI: 8.51 – 21.37]; p = 0.003),

weight loss (hospitalized: 37.31% [95% CI: 29.55 –
45.79]; non-hospitalized: 10.83% [95% CI: 8.23 – 14.12];
p < 0.001), and memory alterations (hospitalized: 34.8%
[95% CI: 23.64 – 47.88]; non-hospitalized: 15.6% [95% CI:
9.64 – 24.32]; p = 0.001). The alteration in smell was
signi cantly higher in non-hospitalized patients
(hospitalized: 12.2% [95% CI: 7.96 – 18.10]; nonhospitalized: 22.19% [95% CI: 11.69 – 38.04]; p = 0.035).
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I n b o t h s t u d i e s, l i m i t a t i o n s fo c u s e d o n t h e
heterogeneity of the selected investigations in aspects
such as design, population, measurement of the
disease (heterogeneity in access to diagnostic tests),
measurement of outcomes (self-diagnosis and
diﬀerences in access to health), and follow-up period. In
addition, there were inconsistencies in the terms used
to describe symptoms, as well as limitations in the
details and strati cation of pre-existing comorbidities,
the severity of the COVID-19, and treatment methods.
Also, the geographical distribution of the participants
was another limitation. For example, few studies on
long the COVID-19 in low- or middle-income countries
were identi ed, no studies were found in the pediatric
population, and analyses strati ed by ethnicity were
also not performed. Other factors that can aﬀect the

measurement of prevalence are the t ype of
predominant variant; thus, the Omicron variant
(B.1.1.529) is related to mild acute symptoms in the
vaccinated population; furthermore, the selection of
articles in the English language excludes other
important studies published in diﬀerent languages.

Associated factors
The evidence came mainly from studies on people with
a history of hospitalization for the COVID-19, included in
the systematic review by Michelen et al. (8) y Maglietta et
al. (12) . There was high heterogeneity between the
studies included in the reviews, given the diﬀerent
operational de nitions for the prognostic factors
evaluated and the outcomes of interest (Table 3).

Table 3. Factors associated with long COVID-19.
Factor

Outcome

Number of studies

OR (CI95%)

Heterogeneity
I2 (%)

Any symptom

8

OR: 1.52 (1.27 – 1.82)

68%

Respiratory symptoms

12

OR: 1.20 (1.00 – 1.45)

65%

Any respiratory symptoms

2

OR: 1.10 (0.83 – 1.47)

63%

Cough

3

OR: 0.99 (0.75 – 1.31)

34%

DLCO<80%

4

OR: 2.28 (0.99 – 5.27)

71%

Dyspnea

4

OR: 1.07 (0.70 – 1.65)

87%

Diﬃculty breathing

2

OR: 1.12 (0.73 – 1.71)

63%

Odynophagia

3

OR: 1.40 (0.94 – 2.07)

0%

Mental health symptoms

7

OR: 1.67 (1.21 – 2.29)

58%

Anxiety

3

OR: 1.95 (1.52 – 2.49)

8%

Severity of

PTSD

3

OR: 2.78 (0.63 – 12.22)

76%

the initial disease

Sleeping diﬃculties

3

OR: 1.26 (0.98 – 1.63)

32.5%

Others

3

OR: 1.72 (1.14 – 2.60)

41%

Fatigue

7

OR: 1.54 (1.32 – 1.79)

49%

Respiratory symptoms

9

OR: 1.66 (1.03 – 2.68)

71%

Cough

2

OR: 1.78 (1.05 – 3.03)

0%

DLCO<80%

6

OR: 2.05 (1.06 – 3.96)

49%

Dyspnea

1

OR: 1.53 (0.66 – 3.54)

NA

Age

Diﬃculty breathing

2

OR: 1.12 (0.73 – 1.71)

63%

Age > 60 years

Fatigue

5

OR: 1.23 (0.73 – 2.07)

71%

Age

Olfactory dysfunction

1

OR: 0.42 (0.19 – 0.91)

1

OR: 2.60 (1.19 – 5.67)

Female Sex

Limitations in functional status
(grade II to IV on the Post-COVID

NA

Functional Status Scale)
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Factor

Outcome

Number of studies

OR (CI95%)

Heterogeneity
I2 (%)

Age ≥ 60 years

Low Quality of Life scores

1

OR: 2.44 (1.33 – 4.47)
vs 0-17 years: p=0.003

Age 50-66 years
vs younger age

Persistence of symptoms
(at 125 days)

1

vs 18-34 years:
p=0.001

Comorbidities
Previous psychiatric
diagnosis

Persistence of depressive
symptoms

1

P=0.006

1 comorbidity

Olfactory dysfunction

1

OR: 0.39 (0.16–0.91)

2 comorbidities≥

Symptoms at follow-up

1

OR: 0.33 (0.19–0.99)
OR: 2.52 (1.58 – 4.02)

1

Reduced FEV1:
ECV: 34.2% vs 9.4%
Diabetes: 28.9% vs 12%
Reduced FVC:
ECV: 29.7% vs 11%

2 comorbidities
Cardiovascular
disease (CVD)
and diabetes

Spirometric abnormalities
3 months after discharge

NA

NA

DLCO: Carbon monoxide diﬀusing capacity; FVC: Forced Vital Capacity; FEV1: Forced Expired Volume in the rst
second; PTSD: post-traumatic stress disorder.

Female gender was associated with the presence of any
long-lasting the COVID-19 symptoms (eight studies;
OR: 1.5 [95% CI: 1.27 – 1.82]; I2 = 68%), with the presence
of mental health symptoms, such as anxiety, posttraumatic stress disorder, insomnia, among others.
(seven studies; OR: 1.7 [95% CI: 1.21 – 2.29]; I2 = 58%),
and with fatigue (seven studies; OR: 1.5 [95% CI: 1.32 –
1.79]; I2 = 49%). However, no association was found
between the female gender and respiratory symptoms
(12 studies; OR: 1.20 [95% CI: 1.00 – 1.45]; I2 = 65%).
The severity of the initial symptoms of the COVID-19
was associated with the persistence of respiratory
symptoms (nine studies; OR: 1.66 [95% CI: 1.03 – 2.68]; I2
= 71%). In the analysis by symptom, the severity of the
initial symptoms was associated with the persistence of
cough (two studies; OR: 1.78 [CI95%: 1.05 – 3.03]; I2 =
0%), and with the diﬀusing capacity of carbon
monoxide ( DLCO) < 80% (six studies; OR: 2.05 [95% CI:
1.06 – 3.96]; I2 = 49%). No statistically signi cant
association was found with the presence of fatigue ( ve
studies; OR: 1.23 [95% CI: 0.73 – 2.07]; I 2 = 71%).
In the review by Michelen et al. , age was not included
in the meta-analysis due to the high variability of the
de nitions for this variable and the diﬀerent
(8)

outcomes. Age ≥ 50-60 years was associated with a
higher frequency of low quality of life scores (1 study),
the persistence of symptoms assessed at 125 days of
follow-up (one study), and a lower frequency of
olfactory dysfunction (one study). Likewise, as age
increased, an increased risk of deterioration in
functional status measured by the post-the COVID-19
functional status scale was observed (one study).
Michelen et al. (8) narratively synthesized the assessment
of the presence of comorbidities and their association
with the long-term persistence of the COVID-19
symptoms. Having a previous diagnosis of psychiatric
illness was signi cantly associated with the persistence
of depressive symptoms (one study). Likewise, having
two or more comorbidities were risk factors for the
persistence of symptoms during follow-up (one study).
An additional study identi ed that the presence of
spirometric abnormalities three months after hospital
discharge was more frequent among those with a
history of cardiovascular disease and diabetes.

Methodological quality of the included
systematic reviews
The quality assessment of the reviews included with
AMSTAR 2 is presented in Table 4. Two of the reviews
(8,12)

Pág. 580

Published by INICIB-URP, 2021

9

Revista de la Facultad de Medicina Humana, Vol. 22 [2021], Iss. 3, Art. 15

had low con dence due to the presence of a critical
weakness (item seven: list of items not provided).
excluded studies and usti cation for exclusions), and

jcon dence was very low in a further review due to two
critical weaknesses (item two: lack of an explicit
statement of the existence of a protocol and item seven
already noted).

Table 4. Assessment of methodological quality according to AMSTAR 2
Criteria
Do the research questions and inclusion criteria for the
review include the PICO components? (YES/NO)

YES

YES

Does the report contain an explicit statement that the
review methods had been established before the
review was conducted and did it justify any signi cant
deviations from the protocol? (YES / YES PARTIAL / NO)

YES

YES

Did the authors explain the selection of study designs
to include in the review? (YES/NO)

YES

YES

Did the authors use a comprehensive literature search
strategy? (YES / YES PARTIAL / NO)

YES

YES
PARTIAL

Did the authors perform the study selection in
duplicate? (YES/NO)YES

YES

YES

YES

Did the authors perform data extraction in duplicate?
(YES/NO)

NO

YES

YES

Did the authors provide a list of excluded studies and
justify the exclusions? (YES / YES PARTIAL / NO)

NO

Did the authors describe the included studies in

YES

YES
PARTIAL

YES

Did the authors use a satisfactory technique to assess
the risk of bias in the individual studies that were
included in the review? (YES / YES PARTIAL / NO)

YES

YES

YES

Did the authors report funding sources for the studies
included in the review? (YES/NO)

YES

If they performed a meta-analysis, did the authors use
appropriate methods for statistical pooling of results?
(YES/ NO/ NO META-ANALYSIS)

YES

YES

YES

Did the authors assess the potential impact of risk of
bias in individual studies on the results of the metaanalysis or other evidence synthesis? (YES/ NO/ NO
META-ANALYSIS)

YES

Did the authors account for the risk of bias in individual
studies when interpreting/discussing the results of the
review? (YES/NO)

YES

YES

YES

Did the review authors provide a satisfactory
explanation and discussion of any observed
heterogeneity in the review results? (BUT)

YES

YES

YES

Did the authors conduct an adequate investigation of
publication bias and discuss its possible impact on the
results of the review? (YES/ NO/ NO META-ANALYSIS)

YES

YES

YES

Did the authors disclose possible sources of con ict of
interest, including the funding they received to conduct
the review? (YES/NO)YES

YES

YES

YES

YES

YES
YES
PARTIAL

Score
Number of critical weaknesses
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Overall Con dence

Low

Low

Critically low

Critical
domains

CONCLUSIONS

of bias.

Long COVID-19 is a problem that persists despite
patients recovering from SARS-CoV-2 infection.
According to the ndings, the prevalence is greater
than 40%, the most frequent clinical manifestations are
weakness, malaise, fatigue, impaired concentration,
and shortness of breath. Female sex, greater severity of
the initial condition, increasing age, and the presence of
comorbidities were found to be associated with longlasting COVID-19 symptoms. Both in the assessment of
prevalence and the analysis of associated factors, the
ndings came from studies with a moderate to high risk

This review has limitations to consider, such as the
restriction to systematic reviews in Spanish or English,
the search was limited to PubMed, and the selection
and extraction of da However, considering the results of
systematic reviews with better methodological quality,
an overview of the best evidence available to date on
this condition is provided and the need for better
quality research for an adequate characterization of
COVID-19 has been identi ed. of long duration and
identi cation of its risk factors.
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